Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 4/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31671289 | 0.96 | ACLY (0.44) | CYP4F2CYP4A11ACLYHIF1ATSHR | |
| SCHEMBL27359921 | 0.89 | DGAT1 (0.35) | CYP4F2CYP4A11ACLYDGAT1PKM | |
| SCHEMBL29816017 | 0.82 | CYP4F2 (0.38) | CYP4F2CYP4A11ACLYHIF1ATSHR | |
| SCHEMBL8291211 | 0.82 | ALDH1A1 (0.48) | CYP4F2CYP4A11ACLYTSHRMAPT | |
| SCHEMBL27725175 | 0.80 | TSHR (0.38) | CYP4F2CYP4A11HIF1ATSHRMAPT | |
| SCHEMBL4096371 | 0.80 | CYP4F2 (0.62) | CYP4F2CYP4A11ACLYTSHRMAPT | |
| SCHEMBL2022397 | 0.79 | DGAT1 (0.44) | CYP4F2CYP4A11TSHRDGAT1PKM | |
| SCHEMBL31671264 | 0.79 | ALDH1A1 (0.50) | CYP4F2CYP4A11ACLYTSHRMAPT | |
| SCHEMBL8170550 | 0.78 | CYP4A11 (0.60) | CYP4F2CYP4A11ACLYTSHRDGAT1 | |
| SCHEMBL1245575 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRMAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| US-20050256034-A1 | Dioxolane analogs for improved inter-cellular delivery | ATTARDO GIORGIO | 2005-11-17 | — | — | US | disclosed |
| EP-1324997-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | Shire Biochem Inc. (CA) | 2003-07-09 | — | — | EP | disclosed |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SHIRE BIOCHEM INC. (CA) | 2003-01-16 | — | — | US | disclosed |
| WO-2002030922-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | SHIRE BIOCHEM INC. (CA) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256034-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | CYP4F2 2002/4885CYP4A11 2932/4885ACLY 1242/4885 |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | CYP4F2 2050/4885CYP4A11 2847/4885ACLY 1345/4885 |
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP4F2 1256/4885CYP4A11 594/4885ACLY 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.